Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?

Leonne E. Philippen, Ellen Dirkx, Jan B. M. Wit, Koos Burggraaf, Leon J. de Windt, Paula A. da Costa Martins*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Web of Science)

Abstract

Heart failure (HF) is the end result of a diverse set of causes such as genetic cardiomyopathies, coronary artery disease, and hypertension and represents the primary cause of hospitalization in Europe. This serious clinical disorder is mostly associated with pathological remodeling of the myocardium, pump failure, and sudden death. While the survival of HF patients can be prolonged with conventional pharmacological therapies, the prognosis remains poor. New therapeutic modalities are thus needed that will target the underlying causes and not only the symptoms of the disease. Under chronic cardiac stress, small noncoding RNAs, in particular microRNAs, act as critical regulators of cardiac tissue remodeling and represent a new class of therapeutic targets in patients suffering from HF. Here, we focus on the potential use of microRNA inhibitors as a new treatment paradigm for HF.
Original languageEnglish
Pages (from-to)1810-1818
JournalMolecular Therapy
Volume23
Issue number12
DOIs
Publication statusPublished - Dec 2015

Cite this